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The importance of stem cells and genomics for 
translational research
The confluence of human stem cell and genome research 
is laden with opportunity. Information gleaned from the 
Human Genome Project (HGP) has already done much 
to  expand  our  understanding  of  human  biology  and 
disease (reviewed in [1]). The same can be said of human 
pluripotent stem cell (hPSC) research involving human 
embryonic stem cells (hESCs) and induced pluripotent 
stem cells (iPSCs). For translational stem cell research, 
especially  where  it  involves  reprogramming  of  mature 
cells to make iPSCs and their subsequent directed differ­
entiation  to  other  clinically  useful  cells  and  tissues, 
obtaining a deeper understanding of the role of genome­
wide  transcriptional  and  epigenetic  alterations  will  be 
invaluable. Taking the stem cells and genomics relation­
ship to the next level seems like a good idea.
The availability of hPSCs has accelerated research into 
the underpinnings of development and genetic disease. 
Such cells provide abundant starting material for a range 
of in vitro studies, for example: (i) tissues representing 
hard­to­access anatomical locations; (ii) a wide variety of 
genetic  backgrounds;  (iii)  disease  models,  using  iPSCs 
derived  from  patients  for  whom  the  investigator  has 
access to a detailed clinical history; and (iv) the opportu­
nity  to  monitor  tissue  genesis  at  its  earliest  stages  in 
health and disease alike (reviewed in [2]). The current 
frequency of papers describing novel hPSC­based model 
systems of human diseases reminds me of the heyday of 
gene mapping/identification studies in the late 1980s and 
early 1990s. Back then, it was commonplace to pick up 
the  latest  issue  of  nearly  any  leading  journal  and  find 
papers  describing  disease­causing  genes.  It  felt  like  a 
human genetics renaissance.
Today, hPSCs are facilitating new types of hypothesis­
driven research in human genetics, including studies of 
complex, multifactorial conditions. When combined with 
powerful and ever­cheaper DNA sequencing technology 
[3]  nothing  short  of  a  second  renaissance  in  human 
genetics research becomes possible. As but one example, 
iPSCs can be used to generate banks of representative 
genotypes in certain diseases. The scalability of cultured 
iPSCs, potential for genetic modification and capacity to 
differentiate  into  disease­affected  tissues  permits 
extensive  studies  of  genotype­phenotype  relationships, 
the  identification  of  disease­modifying  loci  and  more 
(reviewed in [2]).
The public perception of translational stem cell 
and genomics research
The concert of stem cell and genomics research has great 
potential; however, it risks amplifying the sour notes of 
each  when  it  comes  to  public  need,  expectation  and 
vulnera  bility.  The  emergence  of  fraudulent  ‘stem  cell 
clinics’  worldwide  [4]  led  the  International  Society  for 
Stem Cell Research (ISSCR) to make recommendations 
regarding the conduct of translational stem cell research 
[5]. The potential for harm from unproven cellular thera­
pies  further  pushed  the  ISSCR  to  establish  a  website 
providing  advice  to  consumers  [6].  Using  this  website, 
individuals may go so far as to request a review of infor­
mation  provided  by  a  ‘clinic’  offering  stem­cell­based 
treatments.
On  the  side  of  genomics,  the  US  Food  and  Drug 
Administration has become quite interested in direct­to­
consumer  marketing  of  genetic  tests  [7].  A  recent 
commentary by J Craig Venter marking the 10th anniver­
sary  of  the  human  genome  sequence  warned  of  low 
standards in the translation of personal genomic informa­
tion  to  consumers,  including  potentially  ‘deceptive 
marketing’ [8]. It is a story as old as it is unfortunate, in 
which  opportunistic  individuals  and  companies  may 
manipulate hype and hope for financial gain.
Though science is a fascinating endeavor for those of us 
in  the  laboratory,  we  should  remember  that  public 
support of biomedical research typically relates to unmet 
clinical need. Investments in the HGP and hPSC research  © 2010 BioMed Central Ltd
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© 2011 BioMed Central Ltdalike  have  been  sold,  in  part,  by  articulating  their 
potential to improve human health. Many benefits have 
already come to pass from this research and more are in 
store.  Unfortunately,  despite  the  best  of  efforts  within 
laboratories and clinics, a great many people continue to 
suffer to the point of desperation. Societal expectations 
for the fruits of stem cell and personal genomics research 
are  high  but  the  general  understanding  of  each, 
particularly their limitations, is low. This gap in public 
understanding is a particular concern, especially when it 
comes to the evaluation of personal medical risk or the 
drafting of new legislation to regulate science.
Public engagement in translational research
Potentially  far­reaching  projects,  such  as  those  of  the 
ISSCR, are important for improving public understanding 
of  stem  cell  research.  Individual  scientists  willing  and 
able to personally engage with the public and with policy 
makers also have a part to play [9]. Ultimately, people will 
make their own decisions but doing so from an informed 
position is the best possible situation. I urge scientists to 
be engaged. There is too much at stake to do otherwise.
That said, education alone is not the answer, especially 
when tensions emerge between scientists and the public, 
such as in the ideological debate around hESC research, 
or when an individual is motivated by a very personal 
desire  to  improve  the  life  of  a  loved  one.  In  a  recent 
report from the American Academy of Arts and Sciences, 
entitled  Do  Scientists  Understand  the  Public  [10], 
researchers are warned against adopting a ‘deficit model’. 
Such a view holds that ‘disconnects’ between scientists 
and  lay  people  stem  from  public  ignorance  and  that 
simply  educating  people  will  fix  things.  I  am  a  big 
proponent of community education in the sciences but it 
is important to be open­minded when engaging people.
I  think  that  we  best  serve  the  public  by  working  to 
understand what people believe and their reasons for it 
before  presenting  our  position.  This  is  one  difference 
between being an active participant and an authoritarian. 
Motivations are often personal and engagement is most 
effective  when  it  is  considerate  of  individual  points  of 
view,  even  if  they  are  scientifically  flawed.  People 
sometimes do things despite having solid information to 
the contrary, especially if the only other option is to do 
nothing.  This  is  part  of  the  complexity  of  human 
existence  in  general  and  interactions  with  a  medically 
needy but autonomously acting public in particular [11].
The American Academy of Arts and Sciences report 
also  stresses  the  importance  of  anticipating  problems 
before they arise [10]. Researchers need to be ahead of 
the curve in the interplay between science and society, 
including the shaping of policy. Failing to engage early 
puts scientists into a reactionary position from which it is 
difficult  to  promote  change.  Public  involvement  in 
translational stem cell and genomics research will only 
become more important, such as in studies where larger 
and more genetically diverse populations are beneficial, 
not to mention in future clinical trials.
My  bottom  line  is  this:  combining  stem  cell  and 
genome technologies is a terrific idea. I foresee a deeper 
understanding of human development and disease as a 
result of this union and, thus, a shorter path to improved 
therapies.  An  important  corollary  is  that  people  are 
waiting for improvements in medical care and they are 
understandably  impatient.  This  presents  its  own 
opportunities, not only to put new information on the 
table, but to partner with the public and policy makers in 
a way that ensures support. When such relationships also 
promote  greater  consumer  protection  against  sham 
therapies, I fail to see a downside to engagement.
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